ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

OMMH Omnimmune Holdings Inc (CE)

0.0001
0.00 (0.00%)
14 Mar 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Omnimmune Holdings Inc (CE) USOTC:OMMH OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.0001 0.00 00:00:00

- Amended Annual Report (10-K/A)

22/01/2010 9:23pm

Edgar (US Regulatory)




UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

 
FORM 10-K/A
Amendment No. 1
 

 
  (Mark One)  
    x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
     
    For the fiscal year ended December 31, 2008
     
  o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from __________________ to ______________________.
 
Commission File Number: 333-145507

OMNIMMUNE HOLDINGS, INC.  
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)
26-3128407
(IRS Employer Identification No.)
 
Omnimmune Holdings, Inc.
4600 Post Oak Place, Suite 352
Houston, Texas 77027
 (Address of principal executive offices)
 
(713) 622-8400
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to section 12(g) of the Act: None.

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. r   Yes       x No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. r
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes        r No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  r
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
 
Large accelerated filer   r
Accelerated filer   r
Non-accelerated filer     r    (Do not check if a smaller reporting company)
Smaller reporting company   x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).   r  Yes       x No

The estimated aggregate market value of the common stock held by non-affiliates of the registrant (which includes all holders other than executive officers, directors and holders of 10% or more of the outstanding common stock of the registrant) as of June 30, 2008, the last business day of the registrant’s most recently completed second fiscal quarter, was approximately $1,100,000 based on the closing price of the stock as reported by the OTC Bulletin Board on June 30, 2008.

8,814,921 shares of our common stock were issued and outstanding as of April 6, 2009.
 
Documents incorporated by reference: None.

 
 

 

PRELIMINARY NOTE
This Amendment No. 1 to Omnimmune Holdings Inc.’s Annual Report on Form 10-K for the year ended December 31, 2008 amends only the items listed below.  With respect to each item, we are amending the annual report to delete the disclosure under that item contained in our Annual Report on Form 10-K and to replace it in its entirety with the disclosure contained in this amendment. 
 
 


 
TABLE OF CONTENTS

   
Page
     
PART II
   
Item 9A.
1
     
SIGNATURES
 
    2
     
CERTIFICATION
 

 

 
PART II


Management’s Report on Disclosure Controls and Procedures

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) of the Exchange Act. Because of its inherent limitations, internal control over financial reporting is not intended to provide absolute assurance that a misstatement of our financial statements would be prevented or detected.  As required by Exchange Act Rule 13a-15(f), as of the end of the period covered by the Annual Report on Form 10-K for the year ended December 31, 2008, our management, under the supervision and with the participation of the Company's Chief Executive Officer and Chief Financial (and principal accounting) Officer conducted an evaluation of the effectiveness of our internal control over financial reporting with reference to the framework in Internal Control--Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

Based on that evaluation, our Chief Executive Officer and Chief Financial Officer (the same person has both titles) concluded that as of December 31, 2008, due to the material weakness existing in our internal controls, our disclosure controls and procedures were ineffective.
 
Significant Deficiencies in Disclosure Controls and Procedures or Internal Controls
 
We have determined there were disclosure errors in Item 9A - Internal Controls Over Financial Reporting as contained in our Form 10-K for the year ended December 31, 2008, as filed with the SEC on April 15, 2009.  This report did not include all disclosures as required by Item 308T of Regulation S-K.
 
The Company is currently conducting a review in order to design enhanced controls and procedures to remedy this deficiency. The Company is not aware of any other deficiencies in its system of disclosure controls and procedures.

This annual report does not include an audit report of our registered public accounting firm regarding internal control over financial reporting. In addition, management's report on internal control over financial reporting was not subject to attestation by our registered public accounting firm pursuant to temporary rules of the SEC that permit us to provide only management's report in this annual report.

Changes in Internal Control over Financial Reporting
 
Except as described above, there were no changes in internal controls over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially effect, our internal control over financial reporting.
 
1

 
SIGNATURES

In accordance with the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
OMNIMMUNE HOLDINGS, INC.
     
January 22, 2010
   
 
By:
/s/ Harris A. Lichtenstein,                        
 
Name:
Harris A. Lichtenstein, Ph.D.
 
Title:
President, Chief Executive Officer and Director
   
(Principal Executive, Financial, and Accounting Officer)
 
In accordance with the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
  
January 22, 2010
By:
/s/ Harris A. Lichtenstein,                        
 
Name:
Harris A. Lichtenstein, Ph.D.
 
Title:
President, Chief Executive Officer and Director
   
(Principal Executive, Financial, and Accounting Officer)
     
January 22, 2010
By:
/s/ Mark German                                         
 
Name:
Mark S. Germain
 
Title:
Chairman of the Board of Directors
     
January 22, 2010
By:
/s/ Alexander Krichevsky                          
 
Name:
Alexander Krichevsky, D.V.M.
 
Title:
Director
     
January 22, 2010
By:
/s/ Charles Duff                                            
 
Name:
Charles Duff
 
Title:
Director
     
January 22, 2010
By:
/s/ Matthew A. Gonda                                
 
Name:
Matthew A. Gonda, Ph.D.
 
Title:
Director


 
2

 

 


1 Year Omnimmune (CE) Chart

1 Year Omnimmune (CE) Chart

1 Month Omnimmune (CE) Chart

1 Month Omnimmune (CE) Chart